Longterm safety and efficacy of adalimumab and infliximab for uveitis associated with juvenile idiopathic arthritis
Abstract
OBJECTIVE:
Anti-TNF-α agents have significantly changed the management of juvenile idiopathic arthritis (JIA). We evaluated the safety and efficacy of adalimumab (ADA) and infliximab (IFX) for the treatment of JIA-associated uveitis in patients treated for ≥ 2 years.
METHODS: